医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women’s & Reproductive Health, on the Development of Novel Therapeutics to Improve Bioenergetics for Intrauterine Growth Restriction (IUGR)

2020年09月29日 PM11:30
このエントリーをはてなブックマークに追加


 

TOKYO

LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the University of Oxford’s Nuffield Department of Women’s & Reproductive Health, in joint research utilising LUCA Science’s proprietary drug delivery platform technology for the treatment of IUGR.

This collaboration was instigated by Dr Yosuke Matsumiya, the UK project director for LUCA Science, who will be coordinating the research with the University of Oxford.

About the Joint Research
The placenta is a unique organ across which nutrients are transferred from mother to baby. Abnormal placental function causes significant problems in pregnancy, including IUGR.

IUGR affects over 10 million babies worldwide/year with 200,000 deaths related to IUGR and survivors (often delivered prematurely) face not only the sequelae of preterm birth but also increased long-term risks of disease (metabolic & cardiac). The largest global causes of IUGR are malnutrition and/or failure of the placenta to effectively transfer nutrition to the baby.

Currently the only treatment for IUGR is delivery irrespective of gestation. Increasing placental cellular bioenergetics and maintaining its function is a logical alternative solution. This collaboration was formed in order to realise this solution and seeks to address this by specifically delivering therapeutics to the placenta, combining unique technology developed at LUCA Science in Japan with extensive placental research experience at the University of Oxford.

Comment from Dr. Manu Vatish*1 at the University of Oxford.

“We are very excited to be working with LUCA Science to address one of the major obstacles in obstetric care. LUCA Science’s cutting-edge technology provides a unique solution to this intractable clinical problem. Use of their novel solution to deliver mitochondria to placental tissues would increase local energy supply to a starving fetus and be a major step in developing treatments for a condition affecting vast numbers of babies worldwide.”

About LUCA Science
LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Mitochondria are the power plants in our cells that produce energy for our bodies. LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent. The advanced delivery system can be applied not just for mitochondria but also other compounds that can improve bioenergetics in specific cells or tissues.

LUCA Science recently completed $9.8 million Series A financing in September.

*1: Senior Clinical Fellow at the Nuffield Department of Women’s and Reproductive Health.

LUCA Science Inc.

Name

:

LUCA Science Inc.

Headquarters

:

3-8-3, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-0023, Japan

CEO

:

Rick C. Tsai DMD, MD

Established

:

December 25th 2018

Employees

:

12

URL

:

https://luca-science.com

Business

:

Research and development of mitochondrial biopharmaceuticals

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005462/en/

CONTACT

Media Contact:

Tomoaki Shinohara, Hiromi Ishigaki

info@luca-science.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • New Frontier Health Corporation to Announce Third Quarter of 2020 Financial Results on December 2, 2020
  • Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China
  • Mary Kay to Support Sea Turtle Conservation Efforts and Promote Sustainable Eco-tourism Practices With the Nature Conservancy in the Solomon Islands
  • Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
  • World AIDS Day 2020: DKT International Supports New Innovations, Education and Virtual Activities For HIV/AIDS Awareness & Prevention